journal
MENU ▼
Read by QxMD icon Read
search

Journal of Medical Economics

journal
https://www.readbyqxmd.com/read/27919186/economic-evaluation-for-the-us-of-nab-paclitaxel-plus-gemcitabine-versus-folfirinox-versus-gemcitabine-in-the-treatment-of-metastatic-pancreas-cancer
#1
Mahdi Gharaibeh, Ali McBride, J Lyle Bootman, Hitendra Patel, Ivo Abraham
BACKGROUND: Nab-paclitaxel plus gemcitabine (NAB-P+GEM) and FOLFIRINOX have shown superior efficacy over gemcitabine (GEM) in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDA). Though the incremental clinical benefits are modest, both treatments represent significant advances in the treatment of a high-mortality cancer. In this independent economic evaluation for the US, we aimed to estimate the comparative cost-utility and cost-effectiveness of these three regimens from the payer perspective...
December 6, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27919177/economic-burden-of-inadequate-symptom-control-among-us-commercially-insured-irritable-bowel-syndrome-patients-with-diarrhea
#2
Jessica L Buono, Kush Mathur, Amelia J Averitt, David A Andrae
AIMS: To assess healthcare resource use and costs among irritable bowel syndrome (IBS) with diarrhea (IBS-D) patients with and without evidence of inadequate symptom control on current prescription therapies and estimate incremental all-cause costs associated with inadequate symptom control. METHODS: IBS-D patients aged ≥18 years with ≥1 medical claim for IBS (ICD-9-CM 564.1x) and either ≥2 claims for diarrhea (ICD-9-CM 787.91, 564.5x), or ≥1 claim for diarrhea plus ≥1 claim for abdominal pain (ICD-9-CM 789...
December 6, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27841717/nilotinib-versus-dasatinib-as-second-line-therapy-in-patients-with-philadelphia-chromosome-positive-chronic-myeloid-leukemia-in-chronic-phase-who-are-resistant-or-intolerant-to-imatinib-a-cost-effectiveness-analysis-based-on-real-world-data
#3
Nanxin Li, Xi Yang, Liangyi Fan, Todor Totev, Annie Guerin, Lei Chen, Subrata Bhattacharyya, George Joseph
OBJECTIVE: To evaluate the cost-effectiveness of second-line nilotinib vs dasatinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) who are resistant or intolerant to imatinib, from a US third-party perspective. METHODS: A lifetime partitioned survival model was developed to compare the costs and effectiveness of nilotinib vs dasatinib, which included four health states: CP on treatment, CP post-discontinuation, progressive disease (accelerated phase [AP] or blast crisis [BC]), and death...
December 2, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27841726/long-term-cost-effectiveness-of-home-versus-clinic-based-management-of-chronic-heart-failure-the-which-study
#4
Shoko Maru, Joshua M Byrnes, Melinda J Carrington, Simon Stewart, Paul A Scuffham
BACKGROUND: The cost-effectiveness of a heart failure management intervention can be further informed by incorporating the expected benefits and costs of future survival. METHODS: This study compared the long-term costs per quality-adjusted life year (QALY) gained from home-based (HBI) vs specialist clinic-based intervention (CBI) among elderly patients (mean age = 71 years) with heart failure discharged home (mean intervention duration = 12 months). Cost-utility analysis was conducted from a government-funded health system perspective...
December 1, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27826987/healthcare-costs-of-urinary-tract-infections-and-genital-mycotic-infections-among-patients-with-type-2-diabetes-mellitus-initiated-on-canagliflozin-a-retrospective-cohort-study
#5
Tony B Amos, Leslie Montejano, Paul Juneau, Susan C Bolge
OBJECTIVE: To assess the economic impact of urinary tract infections (UTIs) and genital mycotic infections (GMIs) among patients with type 2 diabetes mellitus (T2DM) initiated on canagliflozin. METHODS: Administrative claims data from April 2013 through June 2014 MarketScan(®) databases were extracted. Adults with ≥1 claim for canagliflozin, T2DM diagnosis, and ≥90 days enrollment before and after canagliflozin initiation were propensity score matched to controls with T2DM initiated on other anti-hyperglycemic agents (AHAs)...
November 28, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27885871/continuous-prophylaxis-with-recombinant-factor-ix-fc-fusion-protein-and-conventional-recombinant-factor-ix-products-comparisons-of-efficacy-and-weekly-factor-consumption
#6
Alfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén, Stefan Lethagen, Nora McCormick, Sander Yermakov, Paul Karner
BACKGROUND: Continuous prophylaxis for patients with hemophilia B requires frequent injections that are burdensome and that may lead to suboptimal adherence and outcomes. Hence, therapies requiring less-frequent injections are needed. In the absence of head-to-head comparisons, we compared the first extended-half-life-recombinant factor IX (rFIX) product- recombinant factor IX Fc fusion protein (rFIXFc) - with conventional rFIX products based on annualized bleed rates (ABRs) and factor consumption reported in studies of continuous prophylaxis...
November 25, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27822962/impact-of-apixaban-vs-low-molecular-weight-heparin-vitamin-k-antagonist-on-hospital-resource-use-in-patients-with-venous-thromboembolism
#7
C Browne, T Lanitis, M Hamilton, X Li, R Horbyluk, J Mardekian, T Kongnakorn, A Cohen
BACKGROUND: The clinical and economic benefits associated with apixaban treatment have been established in clinical trials and published economic evaluations. The benefits associated with apixaban could extend to improving hospital efficiencies, potentially influencing hospital resource use, and bed days. The objective of this study is to estimate the impact of 6-month treatment with apixaban vs low molecular weight heparin/vitamin k antagonist (LMWH/VKA) on hospital resource use among patients with venous thromboembolism (VTE)...
November 24, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27822961/the-cost-effectiveness-of-disease-modifying-therapies-for-the-treatment-of-relapsing-remitting-multiple-sclerosis
#8
Duygu Bozkaya, Terrie Livingston, Kristen Migliaccio-Walle, Tanner Odom
BACKGROUND: The safety and efficacy of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has been established; however, it is not clear which provides optimal value, given benefit-risk profiles and costs. AIMS: To compare the cost-effectiveness of current DMTs for patients with RRMS in the US. MATERIALS AND METHODS: A Markov model predicting RRMS course following initiation of a DMT was created comparing outcomes (e...
November 21, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27786570/ulipristal-acetate-for-pre-operative-treatment-of-moderate-to-severe-uterine-fibroids-in-women-of-reproductive-age-in-the-netherlands-cost-minimization-analysis-and-budget-impact-analysis
#9
N Zakiyah, A D I van Asselt, M J Postma
OBJECTIVE: Ulipristal acetate has been found to be non-inferior to other pre-operative treatments of uterine fibroids, particularly leuprolide. The objective of this study was to assess the pharmacoeconomic profile of ulipristal acetate compared to leuprolide for the pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands. The analysis was performed and applied within the framework of the ulipristal acetate submission for reimbursement in 2012...
November 11, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27786569/individualized-cost-effectiveness-analysis-of-patient-centered-care-a-case-series-of-hospitalized-patient-preferences-departing-from-practice-based-guidelines
#10
William V Padula, M Andrew Millis, Aelaf D Worku, Peter J Pronovost, John F P Bridges, David O Meltzer
OBJECTIVE: To develop cases of preference-sensitive care and analyze the individualized cost-effectiveness of respecting patient preference compared to guidelines. METHODS: Four cases were analyzed comparing patient preference to guidelines: (a) high-risk cancer patient preferring to forgo colonoscopy; (b) decubitus patient preferring to forgo air-fluidized bed use; (c) anemic patient preferring to forgo transfusion; (d) end-of-life patient requesting all resuscitative measures...
November 10, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27783533/a-case-control-comparison-of-direct-healthcare-provider-medical-costs-of-chronic-idiopathic-constipation-and-irritable-bowel-syndrome-with-constipation-in-a-community-based-cohort
#11
Linda M Herrick, William M Spalding, Yuri A Saito, James Moriarty, Cathy Schleck
OBJECTIVE: Patients with constipation account for 3.1 million US physician visits a year, but care costs for patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) compared to the general public have received little study. The study aim was to describe healthcare utilization and compare medical costs for patients with IBS-C or CIC vs matched controls from a community-based sample. METHODS: A nested case-control sample (IBS-C and CIC cases) and matched controls (1:2) for each case group were selected from Olmsted County, MN, individuals responding to a community-based survey of gastrointestinal symptoms (2008) who received healthcare from a participating Rochester Epidemiology Project (REP) provider...
November 10, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27780397/healthcare-costs-associated-with-rivaroxaban-or-warfarin-use-for-the-treatment-of-venous-thromboembolism
#12
Craig I Coleman, Christopher Baugh, Concetta Crivera, Dejan Milentijevic, Sheng-Wei Wang, Lang Lu, Winnie W Nelson
INTRODUCTION: Rivaroxaban has been shown to have similar efficacy but less major bleeding than warfarin in randomized trials of patients experiencing venous thromboembolism (VTE). This report sought to assess healthcare costs up to 12-months following an index VTE in patients prescribed either rivaroxaban or warfarin. MATERIALS AND METHODS: This study analyzed claims from the MarketScan Commercial Claims and Encounters Database from November 2011-July 2015. It selected adults newly-diagnosed with VTE (deep vein thrombosis [DVT] or pulmonary embolism [PE]) if they had an outpatient prescription claim for rivaroxaban or warfarin within 7-days of the index event...
October 26, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27776468/the-cost-of-warfarin-treatment-for-stroke-prevention-in-patients-with-non-valvular-atrial-fibrillation-in-mexico-from-a-collective-perspective
#13
Jean Baptiste Briere, Kevin Bowrin, Robert Wood, Tim Holbrook, Jenna Roberts
AIMS: To describe the collective costs of vitamin K antagonist (VKA) treatment for stroke prevention in non-valvular atrial fibrillation (NVAF). VKA drug costs are relatively low but they necessitate frequent international normalized ratio (INR) monitoring. There are currently minimal data describing the economic impact of this in Mexico. MATERIALS AND METHODS: Cardiologists provided data on their NVAF patients (n = 400) to quantify direct medical costs (INR testing, appointments, drug costs)...
October 25, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27774840/cost-effectiveness-of-adding-clostridial-collagenase-ointment-to-selective-debridement-in-individuals-with-stage-iv-pressure-ulcers
#14
Marissa J Carter, Adrienne M Gilligan, Curtis R Waycaster, Kathleen Schaum, Caroline E Fife
OBJECTIVE: The purpose of this study was to determine the cost-effectiveness (from a payer's perspective) of adding clostridial collagenase ointment (CCO) to selective debridement compared with selective debridement alone (non-CCO) in the treatment of stage IV pressure ulcers among patients identified from the US Wound Registry. METHODS: A 3-state Markov model was developed to determine costs and outcomes between the CCO and non-CCO groups over a 2-year time horizon...
October 22, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27754739/retreatment-with-varenicline-is-a-cost-effective-aid-for-smoking-cessation
#15
Kirsi Kautiainen, Heikki Ekroos, Mikko Puhakka, Helena Liira, Juha Laine, Kari Linden, Jarmo Hahl
OBJECTIVE: One quit attempt with varenicline has been found to be a cost-effective smoking cessation intervention. The purpose of this study was to analyze varenicline's cost-effectiveness in patients who relapse during or after the first treatment. A comparison was made between retreatment schema with varenicline and retreatment schema with bupropion, NRT and unaided cessation, and treatment once with varenicline in a Finnish context. METHODS: The two-quit version of BENESCO Markov model was used to follow a cohort of smokers making up to two quit attempts over a lifetime...
October 18, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27737596/clinical-humanistic-and-economic-outcomes-between-drug-eluting-stent-des-and-bare-metal-stent-bms-18-month-follow-up-study
#16
Vivian W Y Lee, Franco W Cheng, Adrian Y Choi, Sam T Fong, Cheuk Man Yu, Bryan P Yan
BACKGROUND: Percutaneous coronary intervention (PCI) is one of the most performed interventions for ischemic heart diseases. In Hong Kong, the total number of patient discharges and deaths for ischemic heart diseases in 2009 was 33,363, including 4,360 deaths. There are over 5,000 cases of PCI yearly. This study aimed to compare clinical, economic and humanistic outcomes among patients receiving drug-eluting stent (DES) or bare metal stent (BMS) in Hong Kong. METHODS: Patients who received stent implantation between 15(th) September, 2009 and 11(th) October, 2010 in Prince of Wales Hospital, Hong Kong, were recruited and followed for 18 months...
October 14, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27676291/mapping-eortc-qlq-c30-to-eq-5d-3l-in-patients-with-colorectal-cancer
#17
Emily-Ruth Marriott, Guy van Hazel, Peter Gibbs, Anthony J Hatswell
AIMS: The primary aim of this study was to perform a mapping of the EORTC-QLQ-C30 scores to EQ-5D-3L for the SIRFLOX study; a large dataset of patients with previously untreated liver-only or liver-dominant metastatic colorectal cancer (mCRC). A secondary aim was to compare the predictive validity of existing mappings from EORTC-QLQ-C30 to EQ-5D-3L conducted in other cancers. METHODS AND MATERIALS: Questionnaires (completed within 529 patients) were used in a linear mixed regression to model EQ-5D-3L utility values (scored using the UK tariff) as a function of the five function scores, nine symptom scores, and the global score from the EORTC-QLQ-C30 questionnaire...
October 13, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27730845/peginterferon-beta-1a-versus-other-self-injectable-disease-modifying-therapies-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-in-scotland-a-cost-effectiveness-analysis
#18
Luis Hernandez, Shien Guo, Hector Toro-Diaz, Stuart Carroll, Syed Feisal Syed Farooq
AIMS: Peginterferon beta-1a 125 mcg administered subcutaneously every two weeks, a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), was approved in January 2015 by the Scottish Medicines Consortium. This study assesses long-term clinical and economic outcomes of peginterferon beta-1a compared with other self-injectable DMTs (interferon beta-1a [22 mcg, 30 mcg, and 44 mcg], interferon beta-1b, and glatiramer acetate 20 mg) in the treatment of RRMS, from the National Health Service and personal social services perspective in Scotland...
October 12, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27724055/estimates-of-the-direct-and-indirect-cost-savings-associated-with-heart-disease-that-could-be-avoided-through-dietary-change-in-the-united-states
#19
John Cawley, Chad Meyerhoefer, Leah G Gillingham, Penny Kris-Etherton, Peter J H Jones
AIMS: Diets high in saturated fat are associated with elevated risk of heart disease. This study estimates the savings in direct (medical care) costs and indirect (job absenteeism) costs in the US from reductions in heart disease associated with substituting monounsaturated fats (MUFA) for saturated fats. MATERIALS AND METHODS: A four-part model of the medical care cost savings from avoided heart disease was estimated using data on 247,700 adults from the 2000-2010 Medical Expenditure Panel Survey (MEPS)...
October 11, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27715356/the-cost-effectiveness-of-5-fu-sa-in-the-treatment-of-actinic-keratoses-of-the-face-and-scalp-in-the-uk-secondary-care-setting
#20
Radek Wojcik, Julia Lowin, David Vilardell, Silvia Maeso, Leonardo Ruiz, John Lear, Colin Morton
OBJECTIVE: The objective of this analysis was to estimate the relative cost-effectiveness of Actikerall * (5-FU-SA) versus cryotherapy in a secondary care setting in the UK, for lesion-directed treatment in patients with actinic keratoses (AK) of the face and scalp. METHODS: The model was a simple decision tree, with a 6-month time horizon. The perspective was that of the UK National Health Service (NHS). Modelled treatment effects included reported per-patient histological clearance and recurrence rates...
October 7, 2016: Journal of Medical Economics
journal
journal
34457
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"